13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting PP2A could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, T cell-specific knockout of PP2A or the terpenoid toxin cantharidin, which inhibits...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
23:46 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest activating PP2A could help treat KRAS-mutant lung cancer. In two human KRAS-mutant lung cancer lines, a previously reported tricyclic sulfonamide-based PP2A activator plus the MEK inhibitor...
20:47 , May 2, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Tumor mutations of 22 genes could help diagnose prostate cancer, and mutations in two of them could help predict patient outcomes. Whole-genome sequencing of 112 primary and metastatic prostate cancer and matched...
18:35 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma; mantle cell lymphoma (MCL) Patient sample and mouse studies suggest inhibiting the pentose phosphate pathway with PP2A inhibitor LB-100, inhibition of G6PD or synergistic combination of both,...
19:40 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Other / Genetic disorders Mouse studies suggest that inhibiting PP2A could treat MECP2 duplication syndrome, an X-linked genetic disorder with neuromotor, developmental and other symptoms. In a mouse model of the syndrome, tool compounds...
00:03 , Aug 24, 2017 |  BC Extra  |  Preclinical News

Inhibiting PP2A reduces MECP2 in neuropsychiatric model

In a paper published in Science Translational Medicine , researchers showed that inhibiting protein phosphatase 2 ( PP2A ; PPP2CA) reduced levels of methyl CpG binding protein 2 ( MECP2 ; RTT), suggesting that modulating...
21:03 , Jul 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest activating PP2A could help treat K-Ras (KRAS)-mutant lung cancer. In five KRAS-mutant human lung cancer cell lines, a previously reported PP2A activator decreased survival compared with...
23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a...
22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...